Literature DB >> 18422440

Declining hepatitis A mortality in the United States during the era of hepatitis A vaccination.

Tara M Vogt1, Matthew E Wise, Beth P Bell, Lyn Finelli.   

Abstract

BACKGROUND: Since the mid-1990s, hepatitis A vaccine has been recommended for US children living in historically high-incidence states and for persons with other risk factors or chronic liver disease (CLD). The incidence of hepatitis A has declined dramatically during the era of vaccination, but trends in mortality are largely unknown.
METHODS: US death certificates from 1990 to 2004 for which hepatitis A was listed as the underlying cause of death were analyzed. Average annual age-adjusted mortality rates during the prevaccine (1990-1995) and post-vaccination recommendation (2000-2004) periods were compared using a Mantel-Haenszel test of association. The number of deaths for which CLD was listed as a contributing cause was determined.
RESULTS: Overall, 1436 deaths due to hepatitis A occurred, averaging 96 annually (range, 142 in 1995 to 54 in 2003). CLD contributed to nearly half of these deaths. Mortality rates paralleled incidence rates, beginning to decline in the mid-1990s and achieving low points in 2003 and 2004. Average rates were 32% lower in the post-vaccination recommendation period than in the prevaccine period (P < .01). The decline was more dramatic for states with (45%; P < .001) than without (23%; P = .002) recommendations.
CONCLUSIONS: Hepatitis A mortality rates have declined over the past decade. CLD remains an important and preventable contributing cause of death due to hepatitis A.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18422440     DOI: 10.1086/586899

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  13 in total

1.  Hepatitis a epidemiology goes global.

Authors:  Scott D Holmberg
Journal:  Clin Infect Dis       Date:  2012-01-11       Impact factor: 9.079

2.  Time trends in pediatric hospitalizations for hepatitis A in Greece (1999-2013): Assessment of the impact of universal infant immunization in 2008.

Authors:  V Papaevangelou; Z Alexopoulou; C Hadjichristodoulou; G Kourlamba; A Katsioulis; K Theodoridou; V Spoulou; M Theodoridou
Journal:  Hum Vaccin Immunother       Date:  2016-05-04       Impact factor: 3.452

3.  Seroprevalence of Hepatitis A among Students Enrolled in Tehran University of Medical Sciences during 2011.

Authors:  Anahita Rabiee; Sina Nikayin; Seyed Reza Hashemi; Mostafa Mohaghegh; Marzieh Amini; Roozbeh Rabiee; Shahin Merat
Journal:  Middle East J Dig Dis       Date:  2013-07

Review 4.  Challenges to mapping the health risk of hepatitis A virus infection.

Authors:  Khayriyyah Mohd Hanafiah; Kathryn H Jacobsen; Steven T Wiersma
Journal:  Int J Health Geogr       Date:  2011-10-18       Impact factor: 3.918

5.  Modelling the force of infection for hepatitis A in an urban population-based survey: a comparison of transmission patterns in Brazilian macro-regions.

Authors:  Ricardo Arraes de Alencar Ximenes; Celina Maria Turchi Martelli; Marcos Amaku; Ana Marli C Sartori; Patricia Coelho de Soárez; Hillegonda Maria Dutilh Novaes; Leila Maria Moreira Beltrão Pereira; Regina Célia Moreira; Gerusa Maria Figueiredo; Raymundo Soares de Azevedo
Journal:  PLoS One       Date:  2014-05-20       Impact factor: 3.240

6.  Considerations on the current universal vaccination policy against hepatitis A in Greece after recent outbreaks.

Authors:  Kassiani Mellou; Theologia Sideroglou; Vassiliki Papaevangelou; Anna Katsiaflaka; Nikolaos Bitsolas; Eleni Verykouki; Eleni Triantafillou; Agoritsa Baka; Theano Georgakopoulou; Christos Hadjichristodoulou
Journal:  PLoS One       Date:  2015-01-15       Impact factor: 3.240

Review 7.  Impact of universal mass vaccination with monovalent inactivated hepatitis A vaccines - A systematic review.

Authors:  Anke L Stuurman; Cinzia Marano; Eveline M Bunge; Laurence De Moerlooze; Daniel Shouval
Journal:  Hum Vaccin Immunother       Date:  2016-10-27       Impact factor: 3.452

8.  Structural basis for neutralization of hepatitis A virus informs a rational design of highly potent inhibitors.

Authors:  Lei Cao; Pi Liu; Pan Yang; Qiang Gao; Hong Li; Yao Sun; Ling Zhu; Jianping Lin; Dan Su; Zihe Rao; Xiangxi Wang
Journal:  PLoS Biol       Date:  2019-04-30       Impact factor: 8.029

Review 9.  Molecular biology and inhibitors of hepatitis A virus.

Authors:  Yannick Debing; Johan Neyts; Hendrik Jan Thibaut
Journal:  Med Res Rev       Date:  2013-05-30       Impact factor: 12.944

10.  Role of immigrants and migrants in emerging infectious diseases.

Authors:  Elizabeth D Barnett; Patricia F Walker
Journal:  Med Clin North Am       Date:  2008-11       Impact factor: 5.456

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.